Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer

References

• Alonso MC, Tabernero JM, Ojeda B, Llanos M, Solà C, Climent MA, et al. A phase III randomized trial of cyclo-phosph-amide, mitoxantrone, and 5-fluoro-uracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Breast Cancer Res Treat 1995; 34: 15–24
   PubMed Web of Science ®Google Scholar
• Bennett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, Cartwright K, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988; 6: 1611–20
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717.
   PubMed Web of Science ®Google Scholar
• Hirvikoski PP, Kumpulainen EJ, Johansson RT. CNF combination as adjuvant treatment in breast cancer patients is well tolerated. Anti-Cancer Drugs 1997; 8: 376–8
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind CH. TNM Classification of Malignant Tumors. New York: Wiley-Liss; 1997. p 123–30.
   Google Scholar
• Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Acta Oncol 1994; 33: 365–9
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81
   Web of Science ®Google Scholar
• SPSS for Windows, Release 11.5 (SPSS Inc, ChicagoIL, USA)
   Google Scholar
• Hirvikoski PP, Kumpulainen EJ, Johansson RT. Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. Breast Cancer Res Treat 1997; 44: 269–74
   PubMed Web of Science ®Google Scholar
• Kumpulainen EJ, Hirvikoski PP, Pukkala E, Johansson RT. Cancer risk after adjuvant chemo- or chemohormonal therapy of breast cancer. Anti-Cancer Drugs 1998; 9: 131–4
   PubMed Web of Science ®Google Scholar
• Brenner H, Hakulinen T. Are patients diagnosed with breast cancer before age 50 years ever cured?. J Clin Oncol 2004; 22: 432–8
   PubMedGoogle Scholar
• Fountzilas G, Polichronis A, Katsohis K, Gennatas K, Toussis D, Skarlos D, et al. Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Study. Oncology 1996; 53: 137–46
   Google Scholar
• Ron IG, Wigler N, Borovik R, Brufman G, Rizel S, Shani A, et al. CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer. A phase III randomized multicenter study. Am J Clin Oncol 2001; 24: 323–7
   Google Scholar
• Ron IG, Wigler N, Borovik R, Peretz T, Shani A, Brenner J, et al. CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups. Am J Clin Oncol 2002; 25: 520–2
   Google Scholar
• Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 560–71
   PubMed Web of Science ®Google Scholar
• Arcangeli G, Pinnarò P, Rambone R, Giannarelli D, Benassi M. A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys 2006; 64: 161–7
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998;352:930–42.
   PubMed Web of Science ®Google Scholar
• Saso R, Kulkarni S, Mitchell P, Treleaven J, Swansbury GJ, Mehta J, et al. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 2000; 83: 91–4
   PubMed Web of Science ®Google Scholar
• Coutinho HM, Groothoff JW, Offringa M, Gruppen MP, Heymans HS. De novo malignancy after paediatric renal replacement therapy. Arch Dis Child 2001; 85: 478–83
   Google Scholar
• Knuckey NW, Stoll J, Jr, Epstein MH. Intracranial and spinal meningiomas in patients with breast carcinoma: Case reports. Neurosurgery 1989; 25: 112–6
   PubMedGoogle Scholar